Skip to content

Study · Non-randomized trial · n = 118 · 2015

4 results

[POSSIBLE DRUG CORRECTION OF LIPID METABOLISM DISTURBANCES ASSOCIATED WITH METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS].

Dontsova EV

Eksperimental'naia i klinicheskaia farmakologiia1 Jan 2015

PMID27051926 (opens in a new tab)PepBankPUB-27051926
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with psoriasis and metabolic syndrome, adding intranasal semax to conventional therapy decreased initially elevated serum total cholesterol, whereas standard treatment had no significant effect.

    In plain wordsIn people with psoriasis and metabolic syndrome, adding semax lowered raised total cholesterol, which standard treatment alone did not change.

    Peptide
    Semax
    Outcome
    DecreaseSerum total cholesterol
    Study

    n = 118

    Comparator
    Conventional therapy alone
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.1% solution, 600 mg/day · intranasal · 10 daysAs given in this study (human).

    Source sentences

    Summary
    led to a decrease in the initially elevated serum levels of total cholesterol, triglycerides, LDL cholesterol and to an increase in the initially reduced levels of HDL cholesterol, in contrast to the standard treatment
    1 context sentence
    Summary · context
    In group 1, 58 patients received conventional therapy, while 60 patients in group 2 received the same with additional 0.1% semax solution intranasally 600 mg/day for 10 days.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with psoriasis and metabolic syndrome, adding intranasal semax to conventional therapy decreased initially elevated serum triglycerides, whereas standard treatment had no significant effect.

    In plain wordsIn people with psoriasis and metabolic syndrome, adding semax lowered raised triglycerides, which standard treatment alone did not change.

    Peptide
    Semax
    Outcome
    DecreaseSerum triglycerides
    Study

    n = 118

    Comparator
    Conventional therapy alone
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.1% solution, 600 mg/day · intranasal · 10 daysAs given in this study (human).

    Source sentences

    Summary
    led to a decrease in the initially elevated serum levels of total cholesterol, triglycerides, LDL cholesterol and to an increase in the initially reduced levels of HDL cholesterol, in contrast to the standard treatment
    1 context sentence
    Summary · context
    In group 1, 58 patients received conventional therapy, while 60 patients in group 2 received the same with additional 0.1% semax solution intranasally 600 mg/day for 10 days.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with psoriasis and metabolic syndrome, adding intranasal semax to conventional therapy decreased initially elevated serum LDL cholesterol, whereas standard treatment had no significant effect.

    In plain wordsIn people with psoriasis and metabolic syndrome, adding semax lowered raised LDL cholesterol, which standard treatment alone did not change.

    Peptide
    Semax
    Outcome
    DecreaseSerum LDL cholesterol
    Study

    n = 118

    Comparator
    Conventional therapy alone
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.1% solution, 600 mg/day · intranasal · 10 daysAs given in this study (human).

    Source sentences

    Summary
    led to a decrease in the initially elevated serum levels of total cholesterol, triglycerides, LDL cholesterol and to an increase in the initially reduced levels of HDL cholesterol, in contrast to the standard treatment
    1 context sentence
    Summary · context
    In group 1, 58 patients received conventional therapy, while 60 patients in group 2 received the same with additional 0.1% semax solution intranasally 600 mg/day for 10 days.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with psoriasis and metabolic syndrome, adding intranasal semax to conventional therapy increased initially reduced serum HDL cholesterol, whereas standard treatment had no significant effect.

    In plain wordsIn people with psoriasis and metabolic syndrome, adding semax raised low HDL cholesterol, which standard treatment alone did not change.

    Peptide
    Semax
    Outcome
    IncreaseSerum HDL cholesterol
    Study

    n = 118

    Comparator
    Conventional therapy alone
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    0.1% solution, 600 mg/day · intranasal · 10 daysAs given in this study (human).

    Source sentences

    Summary
    led to a decrease in the initially elevated serum levels of total cholesterol, triglycerides, LDL cholesterol and to an increase in the initially reduced levels of HDL cholesterol, in contrast to the standard treatment
    1 context sentence
    Summary · context
    In group 1, 58 patients received conventional therapy, while 60 patients in group 2 received the same with additional 0.1% semax solution intranasally 600 mg/day for 10 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.